Latest Content

Two-dose oral R‑MDMA, EMP-01, cuts social anxiety symptoms and real‑world avoidance in phase 2a study, with strong responder rates and good tolerability.

Evidence links some hormonal contraceptives—especially in teens—to higher depression risk; see which types matter and how to monitor mood.

Chatbot makers face rising lawsuits over suicide, addiction, and psychosis.

Vibrance-1 phase 2 results show alixorexton improves narcolepsy type 1 severity, cognition, and fatigue for 13 weeks with good tolerability.

Data suggest PBFT02 therapy boosts progranulin and slows neurodegeneration markers in early FTD.

ASAM’s new youth SUD criteria help clinicians deliver developmentally tailored, prevention-first care with coordinated family and community supports.

Learn more about how sex hormones and prolactin shape brain circuits, revealing new biomarkers and treatment strategies for eating disorders, psychosis, and depression.

Learn more about the treatment of depression, selective serotonin reuptake inhibitors, and pregnancy in this podcast.

Learn how therapists navigate honesty, boundaries, and transference when creative patients bring novels, paintings, or provocative images into psychotherapy.

Dissect psychodermatology with experts in both fields, from the American Academy of Dermatology 2026.

Artemis astronauts spotlight psychiatric medication, mental health support, and trust—revealing why psychiatry’s village mindset strengthens care, leadership, and ethics.

High-potency cannabis surges; psychiatry confronts psychosis risk, dependence, and data gaps—why clinicians must guide safer use now.